Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Solange Peters et al.|The Lancet|2020Cited by 1.8k
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer ConsortiumPetros Grivas, Shuchi Gulati, Ali Raza Khaki et al.|Annals of Oncology|2021Cited by 326
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Alain P. Algazi et al.|European Journal of Cancer|2018Cited by 267
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumorsPaul Savage, Morag Park, Alain Pacis et al.|Communications Biology|2020Cited by 56
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|The Breast|2023Cited by 25